Double-blind randomized 12-month soy intervention had no effects on breast MRI fibroglandular tissue density or mammographic density

Cancer Prevention Research

Volumn 8, Issue 10, 2015, Pages 942-951

  Wu, Anna H ^a   Spicer, Darcy ^a   Garcia, Agustin ^g   Tseng, Chiu Chen ^a   Hovanessian Larsen, Linda ^a   Sheth, Pulin ^a   Martin, Sue Ellen ^a   Hawes, Debra ^a   Russell, Christy ^a   MacDonald, Heather ^a   Tripathy, Debu ^b   Su, Min Ying ^c   Ursin, Giske ^a,d,e   Pike, Malcolm C ^a,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e CANCER REGISTRY OF NORWAY   (Norway)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ISOFLAVONE DERIVATIVE; PLACEBO; TAMOXIFEN; SOYBEAN PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; BREAST DENSITY; CANCER CHEMOTHERAPY; CANCER PATIENT; COMPUTER ANALYSIS; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; ABNORMALITIES; BREAST TUMOR; DIAGNOSTIC IMAGING; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; INTRADUCTAL CARCINOMA; MAMMARY GLAND; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RADIOGRAPHY; SOYBEAN;

ADULT; AGED; BREAST DENSITY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, HUMAN; MIDDLE AGED; RADIOGRAPHY; SOYBEAN PROTEINS; SOYBEANS;

EID: 84943231555     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0125     Document Type: Article

References (55)

1. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008;98:9-14.
2. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: A meta-Analysis of prospective studies. Breast Cancer Res Treat 2011;125:315-23.
3. Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, et al. Soy, red clover, and isoflavones and breast cancer: A systematic review. PLoS One 2013;8:e81968.
4. Nechuta SJ, Caan BJ, Chen WY, Flatt SW, Lu W, Patterson RE, et al. The After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristics. Cancer Causes Control 2011;22: 1319-31.
5. Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, et al. Effects of soy protein and isoflavones on circulating hormone concentrations in pre-And post-menopausal women: A systematic review and meta-Analysis. Hum Reprod Update 2009;15: 423-40.
6. Hooper L,MadhavanG, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast density in pre-And post-menopausal women: A systematic review and meta-Analysis of randomized controlled trials. Hum Reprod Update 2010;16:745-60.
7. Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, et al. Mammographic densities and breast cancer risk. Breast Dis 1998;10: 113-26.
8. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
9. Nie K, Chen JH, Chan S, Chau MK, Yu HJ, Bahri S, et al. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys 2008;35:5253-62.
10. Nie K, Chang D, Chen JH, Hsu CC, Nalcioglu O, Su MY. Quantitative analysis of breast parenchymal patterns using 3D fibroglandular tissues segmented based on MRI. Med Phys 2010;37:217-26.
11. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction inmammographic density and breast cancer risk reduction: A nested case-control study. J Natl Cancer Inst 2011;103: 744-52.
12. Cuzick J, Warwick J, Pinney E,Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8.
13. Brisson J, Brisson B, Cote G,Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
14. Konez O, Goyal M, Reaven RE. Can tamoxifen cause a significant mammographic density change in breast parenchyma? Clin Imaging 2001;25: 303-8.
15. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6.
16. Lienart V, Carly B, Kang X, Guzy L, Sajovitz AM, Liebens F. Effect of preventive hormonal therapy on breast density: A systematic qualitative review. ScientificWorldJournal 2014;2014:942386.
17. Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17: 1696-701.
18. Love S. An efficient resource to accelerate research into the cause and prevention of breast cancer: the Love/Avon Army of Women. Cancer Epidemiol Biomarkers Prev 2013;22:471.
19. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res 2012;5:393-402.
20. Wu AH, Stanczyk FZ, Martinez C, Tseng CC, Hendrich S, Murphy P, et al. A controlled 2-mo dietary fat reduction and soy food supplementation study in postmenopausal women. Am J Clin Nutr 2005; 81:1133-41.
21. Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-95.
22. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
23. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW. Can mammographic densities predict effects of tamoxifen on the breast? J Natl Cancer Inst 1996;88:128-9.
24. Wu AH, Ursin G, Koh WP, Wang R, Yuan JM, Khoo KS, et al. Green tea, soy, and mammographic density in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 2008;17:3358-65.
25. Chen JH, Chang YC, Chang D, Wang YT, Nie K, Chang RF, et al. Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study. Magn Reson Imaging 2011;29:91-8.
26. Lin M, Chen JH, Wang X, Chan S, Chen S, Su MY. Template-based automatic breast segmentation on MRI by excluding the chest region. Med Phys 2013;40:122301.
27. Twaddle NC, Churchwell MI, Doerge DR. High-throughput quantification of soy isoflavones in human and rodent blood using liquid chromatography with electrospray mass spectrometry and tandem mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:139-45.
28. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, et al. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol 2007;25:3024-30.
29. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-A clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-84.
30. Lampe JW. Is equol the key to the efficacy of soy foods? Am J Clin Nutr 2009;89:1664S-7S.
31. Khazen M, Warren RM, Boggis CR, Bryant EC, Reed S, Warsi I, et al. A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging. Cancer Epidemiol Biomarkers Prev 2008; 17:2268-74.
32. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, et al. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One 2013;8:e81653.
33. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008;10:201.
34. Nie K, Su MY, Chau MK, Chan S, Nguyen H, Tseng T, et al. Age-And racedependence of the fibroglandular breast density analyzed on 3D MRI.Med Phys 2010;37:2770-6.
35. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, et al. Red-clover-derived isoflavones and mammographic breast density: A double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res 2004;6:R170-9.
36. Maskarinec G, Verheus M, Steinberg FM, Amato P, Cramer MK, Lewis RD, et al. Various doses of soy isoflavones do not modify mammographic density in postmenopausal women. J Nutr 2009;139:981-6.
37. Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke AA. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev 2002;11:195-201.
38. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, et al. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 2008;14:6-12.
39. MariniH, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: A follow-up study. J Clin Endocrinol Metab 2008;93:4787-96.
40. Verheus M, van Gils CH, Kreijkamp-Kaspers S, Kok L, Peeters PH, Grobbee DE, et al. Soy protein containing isoflavones and mammographic density in a randomized controlled trial in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2632-8.
41. Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP. A 2-year soy intervention in premenopausal women does not change mammographic densities. J Nutr 2004;134:3089-94.
42. Maskarinec G, Franke AA, Williams AE, Hebshi S, Oshiro C,Murphy S, et al. Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13: 1736-44.
43. Delmanto A, Nahas-Neto J, Traiman P, Uemura G, Pessoa EC, Nahas EA. Effects of soy isoflavones on mammographic density and breast parenchyma in postmenopausal women: A randomized, double-blind, placebocontrolled clinical trial. Menopause 2013;20:1049-54.
44. Colacurci N, De Franciscis P, Atlante M, Mancino P, Monti M, Volpini G, et al. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women. Gynecol Endocrinol 2013; 29:209-12.
45. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, et al. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase II trial. Cancer Prev Res 2012;5:309-19.
46. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017-24.
47. Sartippour MR, Rao JY, Apple S, Wu D, Henning S, Wang H, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer 2004;49:59-65.
48. ShikeM, Doane AS, Russo L, Cabal R, Reis-Filo J, Gerald W, et al. The effects of soy supplementation on gene expression in breast cancer: A randomized placebo-controlled study. J Natl Cancer Inst 2014;106(9) pii: dju189.
49. Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, et al. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr 2010;140: 1192S-204S.
50. Messina M, Hilakivi-Clarke L. Early intake appears to be the key to the proposed protective effects of soy intake against breast cancer. Nutr Cancer 2009;61:792-8.
51. White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-10.
52. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001; 10:141-2.
53. Morrow M, Chatterton RT Jr, Rademaker AW, Hou N, Jordan VC, Hendrick RE, et al. A prospective study of variability in mammographic density during the menstrual cycle. Breast Cancer Res Treat 2010;121:565-74.
54. Hovhannisyan G, Chow L, Schlosser A, Yaffe MJ, Boyd NF, Martin LJ. Differences in measured mammographic density in the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2009;18:1993-9.
55. Chen JH, Chen WP, Chan S, Yeh DC, Su MY, McLaren CE. Correlation of endogenous hormonal levels, fibroglandular tissue volume and percent density measured using 3D MRI during one menstrual cycle. Ann Oncol 2013;24:2329-35.